X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Quarterly Results   (VSRM)

Here are the latest quarterly results of VENUS REMEDIES. For more details, see the VENUS REMEDIES financial fact sheet and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

VENUS REMEDIES Quarterly Results

No. of Mths
Qtr. Ending
3
Mar-17
3
Jun-17
3
Sep-17
3
Dec-17
3
Mar-18
3
Jun-18
3
Sep-18
3
Dec-18
8-Qtr Chart
Click to enlarge
Net Sales Rs m798782905931932655809691 
Other income Rs m311132125 
Turnover Rs m801784906933935657821695 
Expenses Rs m614593735754838554644643 
Gross profit Rs m1841891711779410116547 
Depreciation Rs m99102758962828383 
Interest Rs m8081878498779194 
Profit before tax Rs m88105-62-563-125 
Tax Rs m-37000320-5-6 
Profit after tax Rs m458105-94-568-119 
Gross profit margin %23.024.218.819.010.115.520.46.9 
Effective tax rate %-451.20.00.00.0-50.90.0-161.64.4 
Net profit margin %5.71.11.10.6-10.1-8.51.0-17.3 
Diluted EPS Rs 4.0 0.7 0.8 0.5 -8.2 -4.9 0.7 -10.4  
Diluted EPS (TTM) Rs 4.1 3.9 3.7 6.0 -6.1 -11.7 -11.9 -22.8  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: VENUS REMEDIES 3QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON   NATCO PHARMA  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON   NATCO PHARMA  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 623 Points Higher; Realty and Telecom Stocks Witness Buying(Closing)

Indian share markets ended their day on a strong note today after BJP led NDA government got clear mandate in the Lok Sabha Election 2019.

Views on news

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 24, 2019 03:33 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ACTAVIS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS